Product Overview

Empagliflozin 10 mg Tablet is a once‑daily oral medication prescribed for adults with Type 2 diabetes mellitus. Manufactured by Healing Pharma in India, each strip contains ten tablets of 10 mg empagliflozin. The product is available in pack sizes of 100, 200, or 300 tablets, offering flexibility for long‑term therapy.

What is Empagliflozin 10 mg Tablet

Empagliflozin belongs to the class of sodium‑glucose cotransporter‑2 (SGLT2) inhibitors. It reduces blood glucose by blocking the reabsorption of glucose in the kidneys, allowing excess glucose to be excreted in urine. The 10 mg strength is the standard dose recommended as initial therapy or as an add‑on to other antidiabetic agents.

Uses and Benefits

The primary use of Empagliflozin 10 mg is to improve glycemic control in patients with Type 2 diabetes. Clinical studies have demonstrated that treatment leads to:

• Lower fasting and post‑prandial blood glucose levels
• Reduction in glycated hemoglobin (HbA1c) by up to 0.8 % on average
• Modest weight loss, which can be beneficial for overall metabolic health
• Potential cardiovascular risk reduction, especially in patients with existing heart disease

These benefits are supported by data from the National Institutes of Health and the U.S. Food and Drug Administration.

How It Works

Empagliflozin selectively inhibits the SGLT2 protein on the luminal surface of renal proximal tubule cells. By doing so, it decreases glucose reabsorption, increasing urinary glucose excretion. This mechanism operates independently of insulin, making the drug effective even when endogenous insulin secretion is impaired. The resulting natriuretic effect also contributes to modest blood pressure lowering.

Dosage Guidelines

For most adults, the recommended starting dose is 10 mg taken once daily, with or without food. The dose may be adjusted based on renal function, concomitant medications, and therapeutic goals:

• If the estimated glomerular filtration rate (eGFR) is between 45 and 60 mL/min/1.73 m², a reduced dose of 5 mg may be considered.
• For patients with eGFR below 45 mL/min/1.73 m², Empagliflozin is not recommended.
• When used in combination with insulin or sulfonylureas, dose adjustment may be required to minimize hypoglycemia risk.

Patients should be instructed to swallow the tablet whole and to maintain adequate hydration, especially in hot weather or after vigorous exercise.

Side Effects

Like all medications, Empagliflozin can cause adverse effects. Most are mild and transient, but some may require medical attention:

• Genital mycotic infections (e.g., yeast infections) – maintain proper hygiene.
• Urinary tract infections – stay hydrated and monitor symptoms.
• Increased urination, which may lead to dehydration if fluid intake is insufficient.
• Rare but serious events such as ketoacidosis or severe renal impairment – seek medical care if nausea, vomiting, or abdominal pain develop.

For a comprehensive safety profile, refer to the Drugs.com database.

Warnings and Precautions

Before initiating therapy, healthcare providers should assess:

• Renal function – avoid use in patients with eGFR <45 mL/min/1.73 m².
• History of urinary tract infections or genital infections – treat prior to starting.
• Concomitant medications that may increase the risk of hypoglycemia.
• Pregnancy and lactation – Empagliflozin is not recommended for use during pregnancy or while breastfeeding.

Patients should be advised to report any signs of dehydration, such as dizziness, light‑headedness, or reduced urine output, to their physician promptly.

Frequently Asked Questions

1. Can Empagliflozin be used for Type 1 diabetes? No. The drug is approved only for Type 2 diabetes. Use in Type 1 diabetes is not recommended and may increase the risk of ketoacidosis.
2. How long does it take to see a reduction in HbA1c? Most patients experience a measurable decline in HbA1c within 4 to 12 weeks of consistent daily dosing.
3. Is weight loss expected with Empagliflozin? Yes. Clinical trials have shown an average weight loss of 2–3 kg over six months, though individual results vary.
4. Can I take Empagliflozin with other diabetes medications? It can be combined with metformin, sulfonylureas, or insulin, but dosage adjustments may be required to avoid hypoglycemia.
5. What should I do if I miss a dose? Take the missed tablet as soon as you remember, unless it is almost time for the next dose. In that case, skip the missed dose and resume the regular schedule; do not double up.

Related Products

• Tretinoin 0.025% Cream (TRETINOIN)
• Azelax Cream (Azelaic Acid)
• Tretinoin 0.1% Cream (Tretinoin)
• Tretinoin Cream
• Tretinoin 0.05% Cream (TRETINOIN)
• Accufine 40 mg (Isotretinoin)
• Accufine 30 mg (Isotretinoin)
• Tretiheal 0.025% Cream (Tretinoin)
• Tretiheal 0.05% Cream (Tretinoin)
• Tretiheal 0.1% Cream (Tretinoin)
• Accufine 5 mg (Isotretinoin)
• Accufine 20 mg Softgel Capsule (Isotretinoin)